Recurrence of HF hospitalization Total-time approach

Slides:

Advertisements

Similar presentations

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with chronic systolic heart failure.

Advertisements

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Heart rate reduction with ivabradine and health related quality of life in.

analysis from the SHIFT study

THE ROLE OF THE HEART FAILURE SPECIALIST NURSE NHS Grampian Heart Failure Nurses November 2008.

May 23rd, 2012 Hot topics from the Heart Failure Congress in Belgrade.

CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.

Effect of ivabradine on recurrent hospitalization for worsening heart failure: findings from SHIFT S ystolic H eart failure treatment with the I f inhibitor.

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

ACOVE 4: Continuity and Coordination of Care in Vulnerable Elders Continuity is ‘‘care over time by a single individual or team of healthcare professionals’’

Effect of ivabradine on recurrent hospitalization for worsening heart failure: findings from SHIFT S ystolic H eart failure treatment with the I f inhibitor.

By OPAL & Memory Team Improving the Individual Experience – Getting the System Right EARLY DIAGNOSIS INTEGRATED CARE PATHWAY RBCH Model.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results Swedberg K, et al. Lancet. 2010;376(9744):

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with severe chronic systolic.

Barb Supanich, RSM, MD, FAAHPM Holy Cross IP Palliative Care Team November 11, 2010.

Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.

New Technologies & Challenges in optimizing the “heart health” of Australia Professor Simon Stewart Head, Preventative Cardiology

Click to edit Master subtitle style Aetna Behavioral Health Depression Initiatives June 2006.

To know more visit HeartFailure.com © 2015 Novartis Pharma AG, May 2015, GLCM/HTF/0028 HEART FAILURE ECONOMIC BURDEN STATISTICS.

Raised heart rate at discharge after acute heart failure is an independent mortality predictor.

The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT Systolic Heart failure.

Camm J, et al. On Behalf of The SHIFT Gothenburg, Cardiac safety of selective heart rate reduction with Ivabradine in chronic heart failure. Poster, Heart.

S ystolic H eart failure treatment with the If inhibitor ivabradine T rial Michel Komajda and Karl Swedberg on behalf of the Investigators.

Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure Systolic Heart.

Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.

RIGHT CARE INITIATIVE TEAM BASED CARE: A LOCAL EXAMPLE 12/10/12 Phillip Raimondi MD Bridget Levich MSN, CDE University of California Davis Medical Center.

Heart rate in heart failure: Heart rate in heart failure: risk marker or risk factor? A subanalysis of the SHIFT trial on behalf of the Investigators M.

The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.

CAPRICORN Adverse CV Events (Frequency ≥ 1.5%) in Either Treatment Group (Uptitration Phase)

New 2011 SHIFT quality of life substudy Quality of life ( QoL) in heart failure: where do we stand? Therapies that have survival benefits either have a.

Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.

By Megan Kells.  New law mandates that government funded insurances are not responsible for expenses of readmissions within 30 days.  Government’s Perspective:

Ratio of percentile groups

EMPHASIS-HF Extended Follow-up

Cost Effectiveness and Optimal Outcomes in HF

Systolic Heart failure treatment with the If inhibitor ivabradine Trial The effect of heart rate reduction with ivabradine on renal function in patients.

A. Heart failure: A challenge to the healthcare delivery system

Baseline characteristics of patients

(pnoninferiority < )

Heart Failure Prevention: Mission Impossible?

MAGIC-AF Trial design: Patients with persistent atrial fibrillation (AF) and remaining in AF after pulmonary vein isolation alone were randomized to either.

The Heart Failure Team Heart Failure Care Map First 24 hours.

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

Revisiting the Pharmacoeconomics of HF

Figure 2 Global cost of HF per capita in 2012

Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

$13.8 Billion Hip Fractures $8.68 billion (63.1%)

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Svend A. Mortensen et al. JCHF 2014;2:

An audit of the post-hospitalisation pulmonary rehabilitation pathway in a northwest London hospital. An audit of the post-hospitalisation pulmonary rehabilitation.

Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effect of ivabradine on recurrent hospitalization for worsening heart failure:

Peter E. Carson et al. JCHF 2015;3:

Association between cardiovascular disease, cardiovascular risk factors and chronic obstructive pulmonary disease (COPD) on mortality. Association between.

T2DM patients with HF may benefit from SGLT2 inhibitor therapy

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Morbidity and mortality benefits with statin use in observational studies on a logarithmic scale. Morbidity and mortality benefits with statin use in observational.

Pamela E. Scott et al. JACC 2018;71:

Jeffrey Senfield et al. JACEP 2017;3:

Increase of physical activity over time associated with lower HF risk

Characteristics of 3415 patients admitted to hospital with

Cohort and Community Surveillance Components

Orly Vardeny et al. JCHF 2016;4:

One-year cumulative incidence rates of adverse clinical outcomes in 9,428 outpatients with CHF stratified by diabetes status at baseline. One-year cumulative.

Key Data on Improving Outcomes in HF Patients

Effectiveness of vaccination for influenza in the current and any of the 3 previous seasons in preventing nonsevere and severe cases of influenza by season,

International Journal of Cardiology

Dr Donal O’Donoghue National Clinical Director for Kidney Care

Effectiveness of vaccination for influenza in the current and 3 previous seasons in preventing nonsevere and severe cases of influenza. Effectiveness of.

Comparison of heart failure admissions rates per annum (recorded hospital admissions/ population at risk) in western developed countries 1978 to.

Presentation transcript:

Recurrence of HF hospitalization Total-time approach Ivabradine (n=3241) Placebo (n=3264) Hazard ratio p-value 1.2 0.8 0.6 1.0 0.4 Favours ivabradine Favours placebo First hospitalization 514 (16%) 672 (21%) 0.75 p<0.001 Second hospitalization 189 (6%) 283 (9%) 0.66 p<0.001 Third hospitalization 90 (3%) 128 (4%) 0.71 p=0.012 Borer JS et al. Eur Heart J Online, 27 August 2012

Economic burden of chronic HF Primary Care Post-discharge outpatient visits Outpatient referral Hospital admissions Drug treatment Hospitalization accounts for most CHF-associated costs Stewart S et al. Eur J Heart Fail 2002;4:361–71.